System Device for SARS-CoV-2 & Influenza A/B Combo Antigen Rapid Test

Short Description:

REF 500220 Specification 20 Tests/Box
Detection principle Immunochromatographic assay Specimens Nasal / Oropharyngeal swab
Intended Use This is a rapid immunochromatographic assay for the detection of SARS-CoV-2 virus Nucleocapsid Protein antigen in human Nasal/Oropharyngeal swab collected from individuals who are suspected of COVID-19 by their healthcare provider within the first five days of the onset of symptoms. The assay is used as an aid in the diagnosis of COVID-19.

Product Detail

Product Tags

The novel coronaviruses belong to the β genus. COVID-19 is an acute respiratory infectious disease. People are generally susceptible. Currently, the patients infected by the novel coronavirus are the main source of infection; asymptomatic infected people can also be an infectious source. Based on the current epidemiological investigation, the incubation period is 1 to 14 days, mostly 3 to 7 days. The main manifestations include fever, fatigue and dry cough. Nasal congestion, runny nose, sore throat, myalgia and diarrhea are found in a few cases.

Influenza is a highly contagious, acute, viral infection of the respiratory tract. The causative agents of the disease are immunologically diverse, single-strand RNA viruses known as influenza viruses. There are three types of influenza viruses: A, B, and C. Type A viruses are the most prevalent and are associated with most serious epidemics. Type B viruses produce a disease that is generally milder than that caused by type A. Type C viruses have never been associated with a large epidemic of human disease. Both type A and B viruses can circulate simultaneously, but usually one type is dominant during a given season.

SARS-CoV-2  &  Influenza  A/B Antigen Test-2
SARS-CoV-2  &  Influenza  A/B Antigen Test-1

  • Previous:
  • Next:

  • Write your message here and send it to us